Protective effects of compound FLZ, a novel synthetic analogue of squamosamide, on Β-amyloid-induced rat brain mitochondrial dysfunction in vitro

Acta Pharmacologica Sinica

Volumn 30, Issue 5, 2009, Pages 522-529

  Fang, Fang ^a   Liu, Geng Tao ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

amyloid; Compound FLZ; Cytochrome c; Mitochondrial dysfunction; Mitochondrial key enzymes

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CYTOCHROME C; GLUTATHIONE; HYDROGEN PEROXIDE; N [2 (4 HYDROXYPHENYL)ETHYL] 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; NEUROPROTECTIVE AGENT; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME RELEASE; IN VITRO STUDY; MALE; MITOCHONDRION SWELLING; NONHUMAN; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; BENZENEACETAMIDES; BRAIN; CYTOCHROMES C; GLUTATHIONE; KETOGLUTARATE DEHYDROGENASE COMPLEX; MALE; MITOCHONDRIA; MITOCHONDRIAL SWELLING; PEPTIDE FRAGMENTS; PHENOLS; PYRUVATE DEHYDROGENASE (LIPOAMIDE); RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 66749132996     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.45     Document Type: Article

References (44)

1. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative disease. Nature 2006; 443: 787-95.
2. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 2006; 9: 119-26.
3. Bubber P, Haroutunian V, Flsch G, Blass JP, Gibson GE. Mito-chondiral abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005; 57: 695-703.
4. Beal MF. Mitochondria take center stage in aging and neuro-degeneration. Ann Neurol 2005; 58: 495-505.
5. Keil U, Hauptmann S, Bonert A, Scherping I, Eckert A, Muller WE. Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein nutations. J Alzheimers Dis 2006; 9: 139-46.
6. Casley CS, Canevari L, Land JM, Clark JB, Sharp MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 2002; 80: 91-100.
7. Casley CS, Land JM, Sharp MA, Clark JB, Duchen MR, Canevari L. Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 2002; 10: 258-67.
8. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astro-cytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004; 24: 565-75.
9. Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production and cytochrome c release. J Bioenerg Biomermbr 2005; 37: 207-25.
10. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-52.
11. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K. Mitochondrial dysfunction, apoptotic cell death and Alzheimer's disease. Biochem Pharmacol 2003; 66: 1627-34.
12. Feng W, Wei H, Liu G. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol Neurobiol 2005; 31: 295-300.
13. Zhang D, Zhang JJ, Liu GT. Te novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells. Neuropharmacology 2007; 52: 423-9.
14. Fang F, Liu GT. Protective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharmacol Sin 2006; 27: 651-8.
15. 25-35-induced toxicity in SH-SY5Y cells. Acta Pharmacol Sin 2008; 29: 152-60.
16. Zhang D, Hu X, Wei SJ, Liu J, Gao H, Qian L, et al. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinfammation 2008; 5: 21.
17. Levine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993; 2: 404-10.
18. Lai JC, Clark JB. Preparation of synaptic and nonsynaptic mitochondria from mammalian brain. Methods Enzymol 1979; 55: 51-60.
19. Lai JCK, Walsh JM, Dennis SC, Clark JB. Synaptic and non-synaptic mitochondria from rat brain: isolation and characterization. J Neurochem 1977; 28: 625-31.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
21. Moreira PI, Santors MS, Moreno A, Rego AC, Oliveira C. Efect of amyloid β-peptide on permeability transition pore: a comparative study. J Neurosci Res 2002; 69: 257-67.
22. Lai JC, Cooper AJ. Brain α-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and efects of inhibitors. J Neurochem 1986; 47: 1376-86.
23. Canevari L, Clark JB, Bates TE. Beta-amyloid fragement 25-35 selectivity decrease complex IV activity in isolated mitochondria. FEBS Let 1999; 457: 131-4.
24. Elnageh KM, Gaitonde MK. Efect of a defciency of thiamine on brain pyruvate dehydrogenase: enzyme assay by three different methods. J Neurochem 1988; 51: 1482-9.
25. Wharton DC, Tzagolof A. Cytochrome oxidase from beef heart mitochondria. Methods Enzymol 1967; 10: 245-50.
26. Nathan CF, Brukner LH, Silverstein SC, Cohn ZA. Extracellular cytolysis by activated macrophages and granulo cytes I pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med 1979; 149: 84-99.
27. Stossel T P. Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phago-cytotic disorders. Blood 1973; 42: 121-30.
28. Boyne AF, Ellman GL. A methodology for analysis of tissue sulfydryl components. Anal Biochem 1972; 46: 639-53.
29. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21: 3017-23.
30. Baloyannis S, Costa V, Michmizos D. Mitochondrial alterations in Alzheimer's disease. Am J Alzheimers Dis 2004; 19: 89-93.
31. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23: 298-304.
32. Blass JP, Gibson GE, Hoyer S. Te role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis 2002; 4: 225-32.
33. Shofner JM. Oxidative phosphorylation defects and Alzheimer's disease. Neurogenetics 1997; 1: 13-9.
34. Cotrell DA, Borthwick GM, Johnson MA, Ince PG, Turnbull DM. Te role of cytochrome c oxidase defcient hippocampal neurons in Alzheimer's disease. Neuropathol Appl Neurobiol 2002; 28: 390-6.
35. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 2000; 4: 148-55.
36. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004; 89: 1417-26.
37. Fernandez-Vizarra P, Fenandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol Histopathol 2004; 19: 823-44.
38. Teng FY, Tang BL. Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria? Biochem Biophys Res Commun 2005; 328: 1-5.
39. Gibson GE, Blass JP, Beal MF, Victoria B. Te alpha-ketoglutarate- dehydrogenase complex: a mediator between mitochondia and oxidative stress in neurodegeneration. Mol Neurobiol 2005; 31: 43-63.
40. Mancuso M, Siciliano G, Filosto M, Murri L. Mitochondrial dysfunction and Alzheimer's disease: new development. J Alzheimers Dis 2006; 9: 111-7.
41. Ohta S, Ohsawa I. Dysfunction of mitochondria and oxidative stress in the pathogenensis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxifcation. J Alzheimers Dis 2006; 9: 155-66.
42. Xie P, Jiao XZ, Liang XT, Feng WH, Wei HL, Liu GT. Synthesis and antioxiactivity of squamosamide cyclic analogs. Acta Acad Med Sin 2004; 26: 372-8.
43. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 2003; 993: 334-44.
44. Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr. Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 2001; 76: 1050-6.